Companies sponsors |
Daiichi Sankyo UK (quizartinib) |
Others |
Department of Health and Social Care |
|
NHS England |
|
Welsh Government |
Patient carer groups |
Blood Cancer UK |
|
Leukaemia Care |
Professional groups |
Association of Cancer Physicians |
|
Cancer Research UK |
|
Royal College of Pathologists |
|
Royal College of Physicians |
|
Royal College of Radiologists |
Associated public health groups |
None |
Comparator companies |
Jazz Pharmaceuticals (cytarabine, daunorubicin) (confidentiality agreement returned, participating) |
|
Novartis Pharmaceuticals (midostaurin) (confidentiality agreement returned, participating) |
|
Accord Healthcare (cytarabine, |
|
mitoxantrone) (confidentiality agreement not returned, not participating) |
|
Baxter Healthcare (mitoxantrone) (confidentiality agreement not returned, not participating) |
|
Celgene (azacitidine) (confidentiality agreement not returned, not participating) |
|
Eurocept International (amsacrine) (confidentiality agreement not returned, not participating) |
|
Hospira UK (cytarabine) (confidentiality agreement not returned, not participating) |
|
Medac (etoposide) (confidentiality agreement not returned, not participating) |
|
Napp Pharmaceuticals (cytarabine) (confidentiality agreement not returned, not participating) |
|
Neon Healthcare (etoposide) (confidentiality agreement not returned, not participating) |
|
Pfizer (cytarabine) (confidentiality agreement not returned, not participating) |
|
Zentiva UK (daunorubicin) (confidentiality agreement not returned, not participating) |
General commentators |
All Wales Therapeutics and Toxicology Centre |
|
British National Formulary |
|
Department of Health, Social Services and Public Safety for Northern Ireland |
|
Healthcare Improvement Scotland |
|
Medicines and Healthcare products Regulatory Agency |
|
Scottish Medicines Consortium |
|
Welsh Health Specialised Services Committee |
Relevant research groups |
Institute of Cancer Research |